Patent · US Active

Systems and methods for optimized patient specific tissue engineering vascular grafts

US11541149B2 · kind B2 · utility

2Cited by
59References
22Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 12, 2016
Grant dateJan 3, 2023
Priority date
Expiry dateMay 23, 2037

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61L2300/416
  • WIPO fieldMedical technology
  • WIPO sectorInstruments

Abstract

It has been established that optimizing cell seeding onto tissue engineering vascular grafts (TEVG) is associated with reduced inflammatory responses and reduced post-operative stenosis of TEVG. Cell seeding increased TEVG patency in a dose dependent manner, and TEVG patency improved when more cells were seeded, however duration of incubation time showed minimal effect on TEVG patency. Methods of engineering patient specific TEVG including optimal numbers of cells to maintain graft patency and reduce post-operative stenosis are provided. Closed, single-use customizable systems for seeding TEVG are also provided. Preferably the systems are custom-designed based on morphology of the patient specific graft, to enhance the efficacy of cell seeding.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.